Business Context and Reporting Period
Company: Herbalife Ltd.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Global nutrition company selling weight management, targeted nutrition, energy, sports, fitness, and outer nutrition products through a network of independent members across 95 markets.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Sales | $1,281.1 million | $1,314.0 million | $2,545.4 million | $2,566.1 million |
| Gross Profit | $998.0 million (77.9% margin) | $1,012.4 million (77.0% margin) | $1,977.3 million (77.7% margin) | $1,965.9 million (76.6% margin) |
| Operating Income | $80.4 million | $123.4 million | $152.3 million | $193.9 million |
| Net Income | $4.7 million ($0.05 diluted EPS) | $59.9 million ($0.60 diluted EPS) | $29.0 million ($0.29 diluted EPS) | $89.2 million ($0.89 diluted EPS) |
| Operating Cash Flow (YTD) | $116.3 million (vs. $181.8 million YTD 2023) | |||
| Cash & Equivalents | $374.0 million (as of June 30, 2024) | |||
| Total Debt (Carrying Value) | $2,342.7 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 2.5% in Q2 and 0.8% YTD compared to 2023. In local currency, sales increased 0.2% (Q2) and 1.3% (YTD), indicating the decline was driven by foreign exchange headwinds and volume decreases.
- Profitability Compression: Net income dropped 92.2% in Q2 and 67.5% YTD. Key drivers included a $10.5 million loss on debt extinguishment, higher interest expense due to refinancing, and increased SG&A expenses related to restructuring and digital transformation.
- Debt Refinancing: In April 2024, the company refinanced its 2018 Credit Facility and issued $800 million in 12.25% Senior Secured Notes due 2029. This increased the weighted-average interest rate on borrowings from 7.62% (Dec 2023) to 9.34% (June 2024).
- Volume Points: Worldwide Volume Points decreased 6.0% in Q2 and 4.8% YTD, reflecting lower sales volume despite price increases.
Guidance, Outlook, and Risks
- Restructuring & Transformation: The company is executing a "Restructuring Program" (expected total cost ~$70 million) and a "Transformation Program" (expected total cost ~$90 million). These initiatives aim to deliver annual savings of $80 million and $110 million, respectively, starting in 2025 and 2024.
- Digital Investment: Significant capital is being allocated to the "Herbalife One" digital technology program, with approximately $290 million in implementation costs incurred through June 2024. Non-cash amortization of these costs is expected to impact earnings in 2024 and beyond.
- Geographic Performance:
- North America: Sales declined 6.7% (Q2) due to volume decreases.
- Latin America: Sales increased 2.3% (Q2) driven by price increases, despite volume declines.
- Asia Pacific: Sales increased 1.0% YTD, led by growth in India, offset by declines in Indonesia and South Korea.
- China: Sales decreased 7.2% (Q2) but increased 0.8% YTD.
- Legal & Regulatory Risks:
- Tax Contingencies: Significant ongoing tax assessments in Brazil (ICMS), Mexico (VAT), and India. The company has not accrued losses as it believes a loss is not probable, but outcomes remain uncertain.
- FTC Consent Order: The company remains subject to the 2016 FTC Consent Order, which restricts certain marketing practices and distributor compensation in the U.S.
- Subsequent Event: In July 2024, the company completed a sale-leaseback of its Torrance, California office building, expecting to record a gain of approximately $4 million in Q3 2024.
Investor Verification Checklist
- Debt Service Capacity: Verify the impact of the higher interest rate (9.34%) on future cash flows and the ability to meet the 4.50:1.00 leverage ratio covenant under the new 2024 Credit Facility.
- Volume vs. Price Dynamics: Assess whether price increases are masking underlying volume declines, particularly in North America and EMEA, and the sustainability of local currency sales growth.
- Restructuring Execution: Monitor the realization of the projected $190 million in combined annual savings from the Restructuring and Transformation programs against the incurred costs.
- Tax Exposure: Review the status of tax litigation in Brazil, Mexico, and India, as adverse rulings could result in material, unaccrued liabilities.
- Digital ROI: Evaluate the progress and cost-benefit analysis of the "Herbalife One" technology platform, given the significant capital expenditure and ongoing amortization charges.